<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Neuroscience on FinanClub</title>
    <link>https://finan.club/tags/neuroscience/</link>
    <description>Recent content in Neuroscience on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 12 Dec 2023 05:45:41 +0000</lastBuildDate><atom:link href="https://finan.club/tags/neuroscience/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CERE</title>
      <link>https://finan.club/us/cere/</link>
      <pubDate>Tue, 12 Dec 2023 05:45:41 +0000</pubDate>
      
      <guid>https://finan.club/us/cere/</guid>
      <description>score:-8
Chances: Cerevel Therapeutics has a robust neuroscience pipeline with multiple clinical-stage and preclinical candidates, presenting significant growth opportunities in the coming years. The acquisition by AbbVie will provide Cerevel Therapeutics with the necessary resources to expand its research and development efforts, potentially leading to breakthrough therapies in the field of neuroscience diseases.</description>
    </item>
    
  </channel>
</rss>
